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January 31, 2012:539–43for its correlation with and low bias in estimating daytime
ambulatory BP (2–4). Trial qualification requirements summa-
rized in our paper are correct but incomplete: systolic blood
pressure (SBP)160 mm Hg according to the BpTRU protocol was
andatory, along with 2 office cuff readings of SBP 160 mm Hg
within 3 months of enrollment. Resistant hypertension was assured
by requiring 24-h average ambulatory SBP 135 mm Hg and 1
onth of 3 concomitant antihypertensive medications.
Short-term assessment of baroreflex activation therapy (BAT)
esponse was suboptimal, comprised by the BP difference between
nly 2 time points: months 0 and 6. Month 0 proved an inadequate
aseline, whereas high intraindividual BP variability generated
xcess false-positive findings in the control group (1). Baseline
measurement involving longitudinal BP free of surgical effects
would presumably improve statistical power.
Dr. Tsioufis and colleagues postulate that ambulatory data
would alleviate intrapatient BP variability. Although ambulatory
BP could provide supportive findings, such as attenuation of
morning surge, its correlation with BpTRU would make redun-
dant much of the benefit. In any case, greater reduction of SBP and
increased rate of attaining goal BP among patients receiving BAT
stand as clear indicators of therapeutic benefit.
2. Are results uniformly consistent with the assertion that BP
reductions ensue from BAT? Along with BpTRU measurements,
data on vital signs, medications, and medication adherence were
collected. Dr. Tsioufis and colleagues conjecture that BP reduc-
tions associated with BAT could result from intensified medical
therapy. Between months 0 and 6, the number of prescribed
medications decreased in groups A and B by 0.5 and 0.7,
respectively (p  0.001). Medication remained reduced at month
12. No significant differences in number of medications or use of
aldosterone antagonists were observed between groups A and B.
Medication adherence was stable. Thus, increased medication was
not responsible for the reductions in BP observed with BAT.
Dr. Tsioufis and colleagues suggest reductions in heart rate
(HR) accompanying reduced BP could corroborate BAT effi-
cacy. Despite the high prevalence of beta-blockers and sympa-
tholytic agents, HR was significantly reduced among responders
in group A (4.2 beats/min; p  0.01) but not in group B or
mong nonresponders in either group. More impressively,
ignificant correlations were observed between reductions in BP
nd HR in group A at 6 and 12 months and in group B at 12
onths (r  0.21 to 0.26; all p  0.02) but not at 6 months.
hus, BP reductions with BAT were consistently correlated
ith reduced HR.
3. Is the risk-benefit profile of BAT appropriate for resistant
ypertension? BP was clearly reduced among patients with resistant
ypertension receiving BAT. Moreover, design of the next-
eneration implantable barostimulation device, the Barostim neo
CVRx, Inc., Minneapolis, Minnesota) emphasizes safety. To
ate, neo has demonstrated an excellent safety profile in 40
mplanted patients in Europe and Canada. In addition to reaffirm-
ng the established clinical benefits of BAT, we expect to soon
emonstrate safety of the Barostim neo in a randomized, controlled
tudy of patients with resistant hypertension.
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Device Therapy in
Heart Failure Patients
With Chronic Kidney Disease
We read with great interest the recent article in the Journal by
Cannizzaro et al. (1). The researchers provided a great overview of
various trials in the use of implantable cardioverter-defibrillators
(ICDs) and cardiac resynchronization therapy in patients with
chronic kidney disease (CKD) and congestive heart failure (CHF).
According to the U.S. Renal Data System, more than half a
million people were enrolled in the Medicare-funded end-stage
renal disease program at the end of 2008. Cardiovascular deaths
are the leading cause of mortality in patients with CKD. This
increased risk of cardiovascular and all-cause mortality is apparent
even in the early stages of the disease (2).
There is a dearth of randomized controlled trials investigating
the use of therapies in CHF and CKD (3). ICDs are underutilized
in patients with CKD and CHF. We had the opportunity to carry
out a post hoc analysis addressing the impact of renal dysfunction
on survival in a secondary prevention population from the AVID
(Antiarrhythmics Versus Implantable Defibrillators) trial (4,5).
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January 31, 2012:539–43The AVID trial (n  1,016) was a large multicenter randomized
controlled trial designed to evaluate the role of ICDs versus
conventional antiarrhythmic therapy in a secondary prevention
population (6). Patients were assumed to have renal disease if they
had glomerulonephritis, chronic kidney infections, acute tubular
necrosis, renal insufficiency, or chronic renal failure. A single bout
of hematuria, oliguria, renal calculi, or proteinuria did not signify
kidney disease.
The AVID trial had 41 patients with renal disease in the ICD
arm. We found out that renal disease was an independent predictor
of all-cause mortality (n  116; hazard ratio: 1.748; 95% confi-
dence intervals: 1.01 to 3.01; p  0.04) but not cardiac mortality
n  80; hazard ratio: 1.623; 95% confidence intervals: 0.836 to
.153; p  NS). The use of ICDs was protective for secondary
revention of cardiac (but not all-cause) mortality in patients with
enal disease. Thus, cardiac mortality and not all-cause mortality
ould be a more appropriate endpoint in evaluating ICD use for
econdary prevention of cardiac mortality in patients with renal
isease.
We acknowledge that our study was limited because of the lack
f estimated glomerular filtration rate values and information
egarding the end-stage renal disease status of these patients. Our
tudy, however, adds to the existing published reports on the use of
CDs in this cohort of patients. The use of ICDs in CKD and
HF will continue to grab the interest of future researchers
ecause these conditions coexist in epidemic proportions.
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